APRILIOS Trademark

Trademark Overview

On Wednesday, April 6, 2022, a trademark application was filed for APRILIOS with the United States Patent and Trademark Office. The USPTO has given the APRILIOS trademark a serial number of 97350614. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Friday, September 19, 2025. This trademark is owned by Vanda Pharmaceuticals Inc.. The APRILIOS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and medicinal preparations for the treatment, prevention, or amelioration of symptoms of gastroparesis or motion sickness; pharmaceutical and medicinal preparations for the treatment or prevention of nausea or vomiting; all the aforementioned goods containing tradipitant, all being in capsule form for oral administration, and all being available only by prescription; pharmaceutical products for the treatment, prevention, or amelioration of symptoms of gastroparesis or motion sickness; pharmaceutical products for the treatment or prevention of nausea or vomiting; all containing tradipitant; all the aforementioned goods being in capsule form for oral administration, and all being available only by prescription
aprilios

General Information

Serial Number97350614
Word MarkAPRILIOS
Filing DateWednesday, April 6, 2022
Status732 - THIRD EXTENSION - GRANTED
Status DateFriday, September 19, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 12, 2023

Trademark Statements

Goods and ServicesPharmaceutical and medicinal preparations for the treatment, prevention, or amelioration of symptoms of gastroparesis or motion sickness; pharmaceutical and medicinal preparations for the treatment or prevention of nausea or vomiting; all the aforementioned goods containing tradipitant, all being in capsule form for oral administration, and all being available only by prescription; pharmaceutical products for the treatment, prevention, or amelioration of symptoms of gastroparesis or motion sickness; pharmaceutical products for the treatment or prevention of nausea or vomiting; all containing tradipitant; all the aforementioned goods being in capsule form for oral administration, and all being available only by prescription
Translation of Words in MarkThe English translation of APRILIOS in the mark is APRIL.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, April 12, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameVanda Pharmaceuticals Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWashington, DC 20037
Party NameVanda Pharmaceuticals Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWashington, DC 20037

Trademark Events

Event DateEvent Description
Saturday, April 9, 2022NEW APPLICATION ENTERED
Tuesday, April 12, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, January 23, 2023ASSIGNED TO EXAMINER
Thursday, February 9, 2023NON-FINAL ACTION WRITTEN
Thursday, February 9, 2023NON-FINAL ACTION E-MAILED
Thursday, February 9, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, May 5, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, May 5, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, May 5, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, July 19, 2023ASSIGNED TO EXAMINER
Thursday, August 3, 2023FINAL REFUSAL WRITTEN
Thursday, August 3, 2023FINAL REFUSAL E-MAILED
Thursday, August 3, 2023NOTIFICATION OF FINAL REFUSAL EMAILED
Friday, November 3, 2023TEAS REQUEST FOR RECONSIDERATION RECEIVED
Friday, November 3, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, November 3, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, November 7, 2023EXAMINERS AMENDMENT -WRITTEN
Tuesday, November 7, 2023EXAMINERS AMENDMENT E-MAILED
Tuesday, November 7, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, November 7, 2023EXAMINER'S AMENDMENT ENTERED
Tuesday, November 7, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, December 12, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, November 22, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 12, 2023PUBLISHED FOR OPPOSITION
Monday, January 8, 2024EXTENSION OF TIME TO OPPOSE RECEIVED
Sunday, April 21, 2024EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Tuesday, June 4, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, November 1, 2024SOU TEAS EXTENSION RECEIVED
Friday, November 1, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 1, 2024SOU EXTENSION 1 GRANTED
Friday, November 1, 2024SOU EXTENSION 1 FILED
Friday, May 2, 2025SOU TEAS EXTENSION RECEIVED
Saturday, May 3, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, September 19, 2025SOU TEAS EXTENSION RECEIVED
Friday, September 19, 2025SOU EXTENSION 3 FILED
Friday, September 19, 2025SOU EXTENSION 3 GRANTED
Saturday, September 20, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, May 3, 2025SOU EXTENSION 2 GRANTED
Friday, May 2, 2025SOU EXTENSION 2 FILED

Related Keywords

aprilios being prevention treatment pharmaceutical form capsule tradipitant oral available products